Skip to main content

Table 3 Plasma lipid profile and inflammatory mediators before and after simvastatin treatment in patients with CHD and control subjects

From: Impact of matrix metalloproteinase 9 rs3918242 genetic variant on lipid-lowering efficacy of simvastatin therapy in Chinese patients with coronary heart disease

  Controls (n = 186) CHD group (n = 264)
Before treatment After treatment
TG (mmol/l) 1.15 ± 0.35 1.58 ± 0.58* 1.14 ± 0.71§
TC (mmol/l) 4.11 ± 0.37 5.14 ± 0.49* 4.35 ± 0.53§
HDL-C (mmol/L) 1.37 ± 0.31 1.10 ± 0.25* 1.29 ± 0.27§
LDL-C (mmol/L) 2.00 ± 0.51 3.1 ± 0.27* 2.32 ± 0.30§
VLDL-C (mmol/L) 0.75 ± 0.21 1.03 ± 0.24* 0.78 ± 0.16§
MMP-9 (ng/ml) 40.78 ± 9.72 78.17 ± 21.43* 60.32 ± 20.30§
TNF-α (pg/ml) 81.23 ± 39.07 136.95 ± 52.41* 102.37 ± 47.19§
IL-10 (pg/ml) 32.18 ± 12.15 98.65 ± 34.79* 50.31 ± 24.28§
  1. Values are expressed as mean ± SD. Comparison between controls and CHD subjects were by unpaired student T-test; comparison between before and after treatment of statin were by paired student T-test. *P <0.0001 compared with control group; § P <0.0001 compared with before treatment. CHD coronary heart disease, MMP9 matrix metalloproteinase 9, IL-10 interleukin-10, TNF-α TNF-alpha, TC total cholesterol, TG triglyceride, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, VLDL-C very low density lipoprotein cholesterol